Today’s Price Action: Concordia International Corp Stock Is Crashing Now

Today's Price Action: Concordia International Corp Stock Is Crashing Now

The stock of Concordia International Corp (NASDAQ:CXRX) is a huge mover today! About 2.74M shares traded hands. Concordia International Corp (NASDAQ:CXRX) has declined 85.66% since April 13, 2016 and is downtrending. It has underperformed by 89.58% the S&P500.
The move comes after 8 months negative chart setup for the $178.56M company. It was reported on Nov, 15 by Barchart.com. We have $2.71 PT which if reached, will make NASDAQ:CXRX worth $23.21M less.

Concordia International Corp (NASDAQ:CXRX) Ratings Coverage

Out of 9 analysts covering Concordia Healthcare Corp. (NASDAQ:CXRX), 5 rate it a “Buy”, 0 “Sell”, while 4 “Hold”. This means 56% are positive. Concordia Healthcare Corp. has been the topic of 18 analyst reports since August 11, 2015 according to StockzIntelligence Inc. The firm has “Hold” rating by GMP Securities given on Monday, August 15. Laurentian maintained it with “Buy” rating and $55 target price in Tuesday, March 29 report. Scotia Capital maintained Concordia International Corp (NASDAQ:CXRX) rating on Friday, October 16. Scotia Capital has “Sector Outperform” rating and $75 price target. The stock of Concordia International Corp (NASDAQ:CXRX) has “Underperformer” rating given on Monday, August 15 by IBC. The rating was maintained by Canaccord Genuity with “Buy” on Tuesday, August 11. Mackie upgraded Concordia International Corp (NASDAQ:CXRX) rating on Monday, October 19. Mackie has “Speculative Buy” rating and $42.50 price target. The stock of Concordia International Corp (NASDAQ:CXRX) earned “Outperform” rating by RBC Capital Markets on Thursday, October 1. IBC initiated Concordia International Corp (NASDAQ:CXRX) on Monday, November 30 with “Sector Perform” rating. The firm earned “Sector Outperform” rating on Tuesday, September 29 by Scotia Capital. Goldman Sachs initiated Concordia International Corp (NASDAQ:CXRX) on Monday, June 6 with “Neutral” rating.

According to Zacks Investment Research, “Concordia International Corp is a diverse pharmaceutical company which focused on legacy pharmaceutical products and orphan drugs. The company also markets orphan drugs through its Orphan Drug Division, currently consisting of Photofrin(R) for the treatment of certain rare forms of cancer, which is currently undergoing testing for potential new indications. Concordia International Corp, formerly known as Concordia Healthcare Corp, is headquartered in Oakville, Canada.”

Another recent and important Concordia International Corp (NASDAQ:CXRX) news was published by Prnewswire.com which published an article titled: “Concordia International Corp. Announces CEO Transition Plan” on October 21, 2016.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Tags: , ,

Leave a Comment